EPZM News and Press, Epizyme Inc. From 05/06/21

Epizyme (EPZM): Q1 GAAP EPS of -$0.69 misses by $0.12.Revenue of $7.63M (+465.2% Y/Y) beats by $0.76M.2021 Financial GuidanceBased on its current operating plans, Epizyme expects its current cash runway to extend into 2023. Additionally, the Company expects its non-GAAP adjusted operating exp...

Total Revenue of $7.6 Million for 1Q 2021; TAZVERIK ® Net Product Revenues of $6.2 Million Ongoing TAZVERIK Clinical Trials in both Follicular Lymphoma and Prostate Cancer Demonstrate Encouraging Preliminary Safety and Activity Data Investigational New Drug (I...

Epizyme (NASDAQ:EPZM) is scheduled to announce Q1 earnings results on Thursday, May 6th, before market open.The consensus EPS Estimate is -$0.56 (-9.8% Y/Y) and the consensus Revenue Estimate is $6.66M (+393.3% Y/Y).Over the last 1 year, EPZM has beaten EPS estimates 75% of the time and has b...

Epizyme , (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies, today announced that management will host a conference call and webcast to discuss its first quarter 2021 financial results and provide a bu...

Epizyme Inc. (NASDAQ:EPZM) traded today at a new 52-week low of $7.37. This new low was reached on below average trading volume as 220,000 shares traded hands, while the average 30-day volume is approximately 1.4 million shares. Epizyme Inc is a clinical-stage biopharmaceutical company t...

Epizyme is at a multi-year low. Main cause of disappointment is slow sales of Tazverik. Potential is great with label expansion and epigenetic pipeline. For further details see: Epizyme Comeback Is Likely, Price Makes It A Buy

Can-Fite BioPharma Ltd. (CANF) +87% on out-licensing psoriasis, liver disease drug rights.SunLink Health Systems, Inc. (SSY) +55% on announcing $2 Million expansion, capital and operating improvements at Trace Regional Hospital.Annovis Bio, Inc. (ANVS) +37% as ANVS401 improves ...

The following slide deck was published by Epizyme, Inc. in conjunction with this event. For further details see: Epizyme (EPZM) Presents At The Next EPIsode: Rewriting Oncology Treatment with Epigenetics - Slideshow

The following slide deck was published by Epizyme, Inc. in conjunction with this event. For further details see: Epizyme (EPZM) Presents At Barclays Global Healthcare Conference - Slideshow

Epizyme’s Next EPIsode: Vision for Rewriting Oncology Treatment with Epigenetics Showcased New Five-Year Corporate Strategy Preliminary Safety and Activity Data from Ongoing Clinical Trials for TAZVERIK ® Combinations in Follicular Lymphoma and Prostate Cancer ...